(Q46620675)

23 December 2017

title

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms (English)

1 reference

23 December 2017

main subject

gram-positive bacteria

0 references

1 reference

8

Vance G Fowler

1 reference

23 December 2017

13

G Ralph Corey

1 reference

23 December 2017

Martin E Stryjewski

1

object named as

Martin E Stryjewski

1 reference

23 December 2017

Steven L Barriere

11

object named as

Steven L Barriere

1 reference

23 December 2017

author name string

Donald R Graham

2

1 reference

23 December 2017

Samuel E Wilson

3

1 reference

23 December 2017

William O'Riordan

4

1 reference

23 December 2017

David Young

5

1 reference

23 December 2017

Arnold Lentnek

6

1 reference

23 December 2017

Douglas P Ross

7

1 reference

23 December 2017

Alan Hopkins

9

1 reference

23 December 2017

H David Friedland

10

1 reference

23 December 2017

Michael M Kitt

12

1 reference

23 December 2017

Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study

14

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

23 December 2017

Clinical Infectious Diseases

published in

1 reference

23 December 2017

volume

46

1 reference

23 December 2017

issue

11

1 reference

23 December 2017

page(s)

1683-1693

1 reference

23 December 2017

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

cites work

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat

21 January 2018

1 reference

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

21 January 2018

1 reference

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

21 January 2018

1 reference

A clone of methicillin-resistant Staphylococcus aureus among professional football players.

21 January 2018

1 reference

Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections

21 January 2018

1 reference

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections

21 January 2018

1 reference

Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.

21 January 2018

1 reference

Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection

21 January 2018

1 reference

Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods

21 January 2018

1 reference

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

In vitro activity of TD-6424 against Staphylococcus aureus

21 January 2018

1 reference

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

21 January 2018

1 reference

Community-acquired methicillin-resistant Staphylococcus aureus skin infections: a review of epidemiology, clinical features, management, and prevention

21 January 2018

1 reference

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/587896

1 reference

23 December 2017

1 reference

23 December 2017